Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    "carnitine palmitoyltransferase II deficiency"
Show Display Options
Rank Status Study
1 Completed Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects
Conditions: Carnitine Palmitoyltransferase II Deficiency;   Very Long Chain Acyl Coa Dehydrogenase Deficiency
Interventions: Drug: Bezafibrate;   Other: Placebo
2 Unknown  Bezafibrate Trial in CPT2 Deficiency
Condition: Carnitine Palmitoyl Transferase 2 Deficiency
Intervention: Drug: bezafibrate (drug)
3 Active, not recruiting An Open-label Phase 2 Study of UX007 (Triheptanoin) in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD);   Carnitine Palmitoyltransferase (CPT II) Deficiency;   Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency;   Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency;   Trifunctional Protein (TFP) Deficiency
Intervention: Drug: UX007
4 Enrolling by invitation Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies.
Conditions: Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency;   Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency;   Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency;   Trifunctional Protein (TFP) Deficiency;   Carnitine-acylcarnitine Translocase (CACT) Deficiency
Intervention: Drug: UX007
5 Completed High Protein Diet in Patients With Long-chain Fatty Acid Oxidation Disorders
Conditions: Very Long-chain Acyl-CoA Dehydrogenase Deficiency;   Trifunctional Protein Deficiency;   Carnitine Palmitoyltransferase 2 Deficiency;   Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
Intervention: Behavioral: Diet counseling

Indicates status has not been verified in more than two years